Success rates for drugs in clinical development are declining
Between 2001 and 2006 the success rate of a drug from entering phase 1 and progressing to actual launch fell by 23%, over the same period the average time for a drug to complete development has increased by 20%. This is a critical problem for the pharmaceutical and bio-technology industry.
Smarter clinical trials are part of the solution
The FDA and others identify smarter trials, as a key to reversing this trend. Adopters are already realising benefits.
Wyeth Pharmaceuticals reports a trial decision being made 5 months early and savings of $14 million in direct cost (Drug Information Journal | Vol 43, Number 6 | November 2009 | pp 725 ) and a further trial being closed two months early with 180 fewer subjects used, saving $1.5 million (BioResearch Compliance Report | July 1, 2007 | Pickett, Joseph)
Applied systematically better clinical trial design can deliver even greater benefits to a company’s drug development process.
Achieve your clinical trials goals with us
Tessella and Berry Consultants have more than ten-years of experience helping both pharmaceutical and bio-tech organizations achieve a range of goals at enterprise and trial level, across a variety of indications and a range of trial phases. We can help you
- Maximize the impact of your clinical trials on your drug development process
- Make sure your trial answers the right questions about your compound, in the most cost-effective and timely manner
- Apply sophisticated trial design techniques with total confidence